Have a feature idea you'd love to see implemented?
Let us know!
APGE Apogee Therapeutics Inc.
Price (delayed)
$51.86
Market cap
$3.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$2.73B
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with
Highlights
The company's EPS has surged by 86% YoY and by 61% QoQ
The debt has soared by 131% from the previous quarter
APGE's net income has dropped by 82% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of APGE
Market
Valuations
Earnings
Shares outstanding
58.49M
Market cap
$3.03B
Enterprise value
$2.73B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$118.49M
EBITDA
-$117.79M
Free cash flow
-$111.14M
Per share
Balance sheet
Liquidity
EPS
-$2.07
Free cash flow per share
-$1.97
Book value per share
$13.23
Revenue per share
$0
TBVPS
$14.17
Total assets
$800.66M
Total liabilities
$27.02M
Debt
$4.08M
Equity
$773.64M
Working capital
$657.24M
Debt to equity
0.01
Current ratio
27.7
Quick ratio
27.47
Net debt/EBITDA
2.57
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-19.3%
Return on equity
-20%
Return on invested capital
-37.1%
Return on capital employed
-15.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APGE stock price
How has the Apogee Therapeutics stock price performed over time
Intraday
-2.1%
1 week
-5.5%
1 month
-11.24%
1 year
204.34%
YTD
85.61%
QTD
-11.71%
Financial performance
How have Apogee Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$143.76M
Net income
-$118.49M
Gross margin
N/A
Net margin
N/A
Apogee Therapeutics's operating income has shrunk by 156% YoY and by 21% QoQ
APGE's net income has dropped by 82% year-on-year and by 14% since the previous quarter
Growth
What is Apogee Therapeutics's growth rate over time
Valuation
What is Apogee Therapeutics stock price valuation
P/E
N/A
P/B
3.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 86% YoY and by 61% QoQ
APGE's P/B is 18% above its last 4 quarters average of 3.4
APGE's equity is down by 3.5% since the previous quarter
Efficiency
How efficient is Apogee Therapeutics business performance
Apogee Therapeutics's ROA has soared by 61% YoY and by 17% from the previous quarter
The company's return on invested capital rose by 29% QoQ
APGE's return on equity is up by 26% since the previous quarter
Dividends
What is APGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APGE.
Financial health
How did Apogee Therapeutics financials performed over time
Apogee Therapeutics's total liabilities has surged by 53% YoY and by 22% QoQ
The quick ratio has contracted by 27% from the previous quarter
The debt is 99% less than the equity
The debt has soared by 131% from the previous quarter
APGE's equity is down by 3.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.